Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (45 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10121
Sealed predictions
- CRELD1 in dopamine neurons, braak-0.22 (p 0.563) → -0.34 (p 0.367)receipt 10129
Swarm cases
receipt 10129: CRELD1 in dopamine neurons, braak
- power
- full sample -0.12 (p 0.633, n 18), 95% CI -0.56 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.867, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.01, sign flips 1; without severely affected donors -0.12 (p 0.633, n 18). fragile.
- cell type
- strongest in microglia: +0.63 (p 0.0055, n 18) vs -0.12 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CRELD1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CRELD1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.22 p 0.424 (needs p < 2.1e-4)
Receipts
loading the receipts